» Articles » PMID: 36409492

Assessment of Uptake Appropriateness of Computed Tomography for Lung Cancer Screening According to Patients Meeting Eligibility Criteria of the US Preventive Services Task Force

Overview
Journal JAMA Netw Open
Specialty General Medicine
Date 2022 Nov 21
PMID 36409492
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: Currently, computed tomography (CT) is used for lung cancer screening (LCS) among populations with various levels of compliance to the eligibility criteria from the US Preventive Services Task Force (USPSTF) recommendations and may represent suboptimal allocation of health care resources.

Objective: To evaluate the appropriateness of CT LCS according to the USPSTF eligibility criteria.

Design, Setting, And Participants: This cross-sectional study used the 2019 Behavioral Risk Factor Surveillance System (BRFSS) survey. Participants included individuals who responded to the LCS module administered in 20 states and had valid answers to questions regarding screening and smoking history. Data were analyzed between October 2021 and August 2022.

Exposures: Screening eligibility groups were categorized according to the USPSTF 2013 recommendations, and subgroups of individuals who underwent LCS were analyzed.

Main Outcomes And Measures: Main outcomes included LCS among the screening-eligible population and the proportions of the screened populations according to compliance categories established from the USPSTF 2013 and 2021 recommendations. In addition, the association between respondents' characteristics and LCS was evaluated for the subgroup who were screened despite not meeting any of the 3 USPSTF screening criteria: age, pack-year, and years since quitting smoking.

Results: A total of 96 097 respondents were identified for the full study cohort, and 2 subgroups were constructed: (1) 3374 respondents who reported having a CT or computerized axial tomography to check for lung cancer and (2) 33 809 respondents who did not meet any screening eligibility criteria. The proportion of participants who were under 50 years old was 53.1%; between 50 and 54, 9.1%; between 55 and 79, 33.8%; and over 80, 4.0%. A total of 51 536 (50.9%) of the participants were female. According to the USPSTF 2013 recommendation, 807 (12.8%) of the screening-eligible population underwent LCS. Among those who were screened, only 807 (20.9%) met all 3 screening eligibility criteria, whereas 538 (20.1%) failed to meet any criteria. Among respondents in subgroup 2, being of older age and having a history of stroke, chronic obstructive pulmonary disease, kidney disease, or diabetes were associated with higher likelihood of LCS.

Conclusions And Relevance: In this cross-sectional study of the BRFSS 2019 survey, the low uptake rate among screening-eligible patients undermined the goal of LCS of early detection. Suboptimal screening patterns could increase health system costs and add financial stress, psychological burden, and physical harms to low-risk patients, while failing to provide high-quality preventive services to individuals at high risk of lung cancer.

Citing Articles

A Novel Automated Algorithm to Identify Lung Cancer Screening from Free Text of Radiology Orders.

Rustagi A, Vali M, Graham F, Lum E, Slatore C, Keyhani S J Gen Intern Med. 2025; .

PMID: 40000524 DOI: 10.1007/s11606-025-09429-2.


Lung Cancer Screening Participation Among Indigenous Peoples Worldwide: A Systematic Review of Challenges and Opportunities.

Belachew S, Bizuayehu H, Diaz A, Jahan S, Crengle S, Fong K Health Promot J Austr. 2025; 36(2):e70001.

PMID: 39994911 PMC: 11850951. DOI: 10.1002/hpja.70001.


Design considerations and challenges in the CHinA National CancEr Screening (CHANCES) trial and Tomosynthesis Mammographic Imaging Screening Trial (TMIST).

Hu P, Steingrimsson J, Cole E, Cormack J, Dunn B, Gatsonis C J Natl Cancer Inst Monogr. 2025; 2025(68):42-48.

PMID: 39989037 PMC: 11848039. DOI: 10.1093/jncimonographs/lgae049.


Identifying the population to be targeted in a lung cancer screening programme in Denmark.

Fernandez Montejo M, Saghir Z, Bodtger U, Jepsen R, Lynge E, Lophaven S BMJ Open Respir Res. 2024; 11(1.

PMID: 39721745 PMC: 11752008. DOI: 10.1136/bmjresp-2024-002499.


The Potential Benefit of a Novel Urine Biosensor Platform for Lung Cancer Detection in the Decision-Making Process: From the Bench to the Bedside.

Wiesel O, Suharev T, Awad A, Abzah L, Laser-Azogui A, Mark Danieli M J Clin Med. 2024; 13(20).

PMID: 39458114 PMC: 11508546. DOI: 10.3390/jcm13206164.


References
1.
Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

2.
Yong P, Sigel K, Rehmani S, Wisnivesky J, Kale M . Lung Cancer Screening Uptake in the United States. Chest. 2020; 157(1):236-238. PMC: 7609956. DOI: 10.1016/j.chest.2019.08.2176. View

3.
Sabik L, Adunlin G . The ACA and Cancer Screening and Diagnosis. Cancer J. 2017; 23(3):151-162. PMC: 5445928. DOI: 10.1097/PPO.0000000000000261. View

4.
Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

5.
Zahnd W, Eberth J . Lung Cancer Screening Utilization: A Behavioral Risk Factor Surveillance System Analysis. Am J Prev Med. 2019; 57(2):250-255. DOI: 10.1016/j.amepre.2019.03.015. View